The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the ‘place’ of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalExpert Review of Anticancer Therapy
DOIs
Publication statusAccepted/In press - Apr 23 2016

Fingerprint

trabectedin
Liposarcoma
Leiomyosarcoma
Safety
Sarcoma
Therapeutics

Keywords

  • combination therapy
  • duration of treatment
  • histology driven therapy
  • L-Sarcoma
  • leiomyosarcoma
  • liposarcoma
  • mechanism of action
  • myxoid liposarcoma
  • second line options
  • Trabectedin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

@article{90c68f9f15844a05bee8e62fa50d06b7,
title = "The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma",
abstract = "The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the ‘place’ of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management.",
keywords = "combination therapy, duration of treatment, histology driven therapy, L-Sarcoma, leiomyosarcoma, liposarcoma, mechanism of action, myxoid liposarcoma, second line options, Trabectedin",
author = "Maristella Saponara and Silvia Stacchiotti and Alessandro Gronchi",
year = "2016",
month = "4",
day = "23",
doi = "10.1080/14737140.2016.1174582",
language = "English",
pages = "1--12",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma

AU - Saponara, Maristella

AU - Stacchiotti, Silvia

AU - Gronchi, Alessandro

PY - 2016/4/23

Y1 - 2016/4/23

N2 - The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the ‘place’ of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management.

AB - The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the ‘place’ of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management.

KW - combination therapy

KW - duration of treatment

KW - histology driven therapy

KW - L-Sarcoma

KW - leiomyosarcoma

KW - liposarcoma

KW - mechanism of action

KW - myxoid liposarcoma

KW - second line options

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84964543162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964543162&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1174582

DO - 10.1080/14737140.2016.1174582

M3 - Article

SP - 1

EP - 12

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

ER -